Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Arroyo

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Expert Review of Neurotherapeutics|September 22, 2018
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosisRafael Arroyo González
The International Journal of Neuroscience|July 4, 2013
Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE studyRafael Arroyo, Mariona Massana, Carlos Vila
Expert Review of Pharmacoeconomics & Outcomes Research|April 12, 2011
Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' studyRafael Arroyo, Carlos Vila, Steve Clissold
Journal of Comparative Effectiveness Research|October 3, 2014
Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticityRafael Arroyo, Carlos Vila, Kerry L Dechant
Medicina Clinica|March 4, 2015
[Monoclonal antibodies for the treatment of multiple sclerosis]Victoria Galán Sánchez-Seco, Ignacio Casanova Peño, Rafael Arroyo González
Journal of Medical Economics|January 6, 2012
Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patientsRainel Sánchez-de la Rosa, Eliazar Sabater, Miguel Angel Casado, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 6, 2007
Human herpesvirus-6 and multiple sclerosis: relapsing-remitting versus secondary progressiveRoverto Alvarez-Lafuente, Virginia de las Heras, Marta García-Montojo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 6, 2007
JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating eventRoberto Alvarez-Lafuente, Marta García-Montojo, Virginia De Las Heras, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 6, 2007
Clinical parameters and HHV-6 active replication in relapsing-remitting multiple sclerosis patientsRoberto Alvarez-Lafuente, Marta García-Montojo, Virginia De las Heras, et al.
Journal of Neurovirology|December 22, 2007
Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patientsMarta Garcia-Montojo, Virginia De Las Heras, Manuel Bartolome, et al.
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Expert Review of Neurotherapeutics|September 22, 2018
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosisRafael Arroyo González
The International Journal of Neuroscience|July 4, 2013
Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE studyRafael Arroyo, Mariona Massana, Carlos Vila
Expert Review of Pharmacoeconomics & Outcomes Research|April 12, 2011
Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' studyRafael Arroyo, Carlos Vila, Steve Clissold
Journal of Comparative Effectiveness Research|October 3, 2014
Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticityRafael Arroyo, Carlos Vila, Kerry L Dechant
Medicina Clinica|March 4, 2015
[Monoclonal antibodies for the treatment of multiple sclerosis]Victoria Galán Sánchez-Seco, Ignacio Casanova Peño, Rafael Arroyo González
Journal of Medical Economics|January 6, 2012
Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patientsRainel Sánchez-de la Rosa, Eliazar Sabater, Miguel Angel Casado, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 6, 2007
Human herpesvirus-6 and multiple sclerosis: relapsing-remitting versus secondary progressiveRoverto Alvarez-Lafuente, Virginia de las Heras, Marta García-Montojo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 6, 2007
JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating eventRoberto Alvarez-Lafuente, Marta García-Montojo, Virginia De Las Heras, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 6, 2007
Clinical parameters and HHV-6 active replication in relapsing-remitting multiple sclerosis patientsRoberto Alvarez-Lafuente, Marta García-Montojo, Virginia De las Heras, et al.
Journal of Neurovirology|December 22, 2007
Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patientsMarta Garcia-Montojo, Virginia De Las Heras, Manuel Bartolome, et al.
Pageof 12